Pasithea Therapeutics Corp. (KTTA) 10-Year Financial Performance & Capital Metrics

KTTA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.Show more

Revenue $0
EBITDA -$14M +11.3%
Net Income -$14M +12.9%
EPS (Diluted) -12.69 +2.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -72.83% -50.3%
ROIC -142.41% -1.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 10.6% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.28%

ROCE

10Y Avg-38.13%

5Y Avg-38.13%

3Y Avg-49.4%

Latest-74.17%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	15.06K	0	0	0
Revenue Growth %	-	-	-1%	-	-
Cost of Goods Sold+	0	17.27K	5.09K	0	0
COGS % of Revenue	-	1.15%	-	-	-
Gross Profit+	0	-2.21K	-5.09K	0	0
Gross Margin %	-	-0.15%	-	-	-
Gross Profit Growth %	-	-	-1.3%	1%	-
Operating Expenses+	61.48K	4.51M	12.58M	15.98M	14.25M
OpEx % of Revenue	-	299.11%	-	-	-
Selling, General & Admin	0	0	9.92M	0	7.05M
SG&A % of Revenue	-	-	-	-	-
Research & Development	0	0	2.67M	8.1M	7.2M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	61.48K	4.51M	0	7.88M	0
Operating Income+	-61.48K	-4.51M	-12.59M	-15.98M	-14.25M
Operating Margin %	-	-299.26%	-	-	-
Operating Income Growth %	-	-72.32%	-1.79%	-0.27%	0.11%
EBITDA+	0	-4.51M	-12.58M	-15.33M	-13.6M
EBITDA Margin %	-	-299.17%	-	-	-
EBITDA Growth %	-	-	-1.79%	-0.22%	0.11%
D&A (Non-Cash Add-back)	61.48K	1.38K	5.09K	648.45K	649.03K
EBIT	-61.48K	-4.51M	-11.73M	-15.98M	-14.25M
Net Interest Income+	0	-508	-102	0	423.18K
Interest Income	0	0	0	0	423.18K
Interest Expense	0	508	102	0	0
Other Income/Expense	0	2.33M	861.09K	471.61K	345.38K
Pretax Income+	-61.48K	-2.17M	-11.73M	-15.51M	-13.9M
Pretax Margin %	-	-144.3%	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1.19%	1.03%	1%
Net Income+	-61.48K	-2.17M	-13.94M	-15.96M	-13.9M
Net Margin %	-	-144.3%	-	-	-
Net Income Growth %	-	-34.36%	-5.41%	-0.15%	0.13%
Net Income (Continuing)	-61.48K	-2.17M	-11.73M	-15.51M	-13.9M
Discontinued Operations	0	0	-2.21M	-453.91K	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.06	-1.89	-10.34	-13.01	-12.69
EPS Growth %	-	-30.82%	-4.47%	-0.26%	0.02%
EPS (Basic)	-0.06	-1.89	-10.34	-12.65	-12.69
Diluted Shares Outstanding	688.92K	1.15M	1.26M	1.23M	1.1M
Basic Shares Outstanding	688.92K	1.15M	1.26M	1.26M	1.1M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	247.96K	53.3M	34.08M	16.69M	7.37M
Cash & Short-Term Investments	243.65K	52.97M	33.09M	16.33M	6.92M
Cash Only	243.65K	52.97M	33.09M	16.33M	6.92M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	40.5K	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	426.45K	104.71K	142.94K
Total Non-Current Assets+	0	20.12K	11.1M	9.42M	8.7M
Property, Plant & Equipment	0	20.12K	625.63K	220.48K	122.34K
Fixed Asset Turnover	-	0.75x	-	-	-
Goodwill	0	0	1.26M	1.26M	1.26M
Intangible Assets	0	0	8.57M	7.94M	7.31M
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	643.38K	0	0
Total Assets+	247.96K	53.32M	45.18M	26.12M	16.06M
Asset Turnover	-	0.00x	-	-	-
Asset Growth %	-	214.04%	-0.15%	-0.42%	-0.38%
Total Current Liabilities+	6.6K	447.28K	1.88M	2.63M	1.12M
Accounts Payable	6.6K	0	1.48M	0	1.12M
Days Payables Outstanding	-	-	106.15K	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	447.28K	235.88K	2.55M	0
Current Ratio	37.55x	119.17x	18.15x	6.34x	6.58x
Quick Ratio	37.55x	119.17x	18.15x	6.34x	6.58x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	1.45M	804.21K	84.37K	162.17K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	344.02K	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	1.45M	460.19K	84.37K	162.17K
Total Liabilities	6.6K	1.9M	2.68M	2.72M	1.28M
Total Debt+	0	0	504.38K	81.68K	0
Net Debt	-243.65K	-52.97M	-32.58M	-16.25M	-6.92M
Debt / Equity	-	-	0.01x	0.00x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-8872.86x	-123421.28x	-	-
Total Equity+	241.35K	51.42M	42.5M	23.4M	14.78M
Equity Growth %	-	212.05%	-0.17%	-0.45%	-0.37%
Book Value per Share	0.35	44.70	33.67	19.08	13.49
Total Shareholders' Equity	241.35K	51.42M	42.5M	23.4M	14.78M
Common Stock	14.94K	17.68K	130	104	139
Retained Earnings	-40.98K	-2.21M	-19.36M	-35.32M	-49.58M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	-10.56K	-661	-4.65K	-7.17K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.69K	-3.17M	-13.69M	-13.43M	-13.92M
Operating CF Margin %	-	-210.73%	-	-	-
Operating CF Growth %	-	-81.04%	-3.31%	0.02%	-0.04%
Net Income	-40.98K	-2.17M	-11.73M	-15.51M	-13.9M
Depreciation & Amortization	0	1.38K	5.09K	648.45K	649.03K
Stock-Based Compensation	0	471.25K	0	592.27K	0
Deferred Taxes	0	-2.33M	0	0	0
Other Non-Cash Items	0	750K	-2.81M	-732.57K	851.5K
Working Capital Changes	2.29K	111.23K	845.35K	1.57M	-1.52M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	440.68K	0	0	0
Cash from Investing+	0	-21.5K	-2.93M	399.01K	0
Capital Expenditures	0	-21.5K	-107.1K	-34.3K	0
CapEx % of Revenue	-	1.43%	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-626.9K	433.31K	0
Cash from Financing+	282.34K	55.93M	-3.21M	-3.73M	4.52M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	5.69M	-3.21M	0	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-38.69K	-3.2M	-13.8M	-13.46M	-13.92M
FCF Margin %	-	-212.16%	-	-	-
FCF Growth %	-	-81.59%	-3.32%	0.02%	-0.03%
FCF per Share	-0.06	-2.78	-10.93	-10.97	-12.70
FCF Conversion (FCF/Net Income)	0.63x	1.46x	0.98x	0.84x	1.00x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-25.47%	-8.41%	-29.68%	-48.44%	-72.83%
Return on Invested Capital (ROIC)	-	-	-225.65%	-140.47%	-142.41%
Gross Margin	-	-14.69%	-	-	-
Net Margin	-	-14430.49%	-	-	-
Debt / Equity	-	-	0.01x	0.00x	-
Interest Coverage	-	-8872.86x	-123421.28x	-	-
FCF Conversion	0.63x	1.46x	0.98x	0.84x	1.00x
Revenue Growth	-	-	-100%	-	-

Frequently Asked Questions

Growth & Financials

Pasithea Therapeutics Corp. (KTTA) grew revenue by 0.0% over the past year. Growth has been modest.

Pasithea Therapeutics Corp. (KTTA) reported a net loss of $13.5M for fiscal year 2024.

Dividend & Returns

Pasithea Therapeutics Corp. (KTTA) has a return on equity (ROE) of -72.8%. Negative ROE indicates the company is unprofitable.

Pasithea Therapeutics Corp. (KTTA) had negative free cash flow of $12.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener